Key result
Recent advances improve the molecular understanding, prevention, and treatment of dose-dependent anthracycline cardiotoxicity.
Why the study?
Anthracyclines are limited by cumulative dose-dependent cardiotoxicity, and the underlying biological mechanisms remain incompletely understood despite decades of research.
This review summarizes the incidence, risk factors, pathophysiology, and recent molecular insights regarding anthracycline-induced cardiotoxicity, as well as prevention and treatment strategies.
Answers are grounded in this paper and cite their sources.
Continues to constrain anthracycline chemotherapy; extends molecular insights while leaving optimal cardioprotection open for prospective trials.
Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers. Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite more than five decades of research, the biological mechanisms underlying anthracycline cardiotoxicity are not completely understood. In this review, we discuss the incidence, risk factors, types, and pathophysiology of anthracycline cardiotoxicity, as well as methods to prevent and treat this condition. We also summarize and discuss advances made in the last decade in the comprehension of the molecular mechanisms underlying the pathology.
No takes yet. Share an insight, caveat, or question.
Sawicki et al. (2020) conducted a review in Anthracycline cardiotoxicity. Anthracycline cardiotoxicity remains a dose-dependent limitation of chemotherapy, with recent advances improving the comprehension of its molecular mechanisms, prevention, and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: